Quality indicators for breast cancer care
The table below shows that Legacy Cancer Institute outperforms other cancer programs on key quality benchmarks, established by the American College of Surgeons Commission on Cancer (CoC). It also shows the percent of our breast cancer patients treated according to the highest, nationally-recognized standards of care developed through the CoC's National Accreditation Program for Breast Centers (NAPBC).
Legacy Cancer Institute outperforms its peers on key quality benchmarks
|
For women with breast cancer
|
Legacy Cancer Institute
|
Pacific Region CoC Programs
|
All CoC Programs
|
NAPBC program standard |
| Needle/core biopsy is performed prior to surgical treatment for breast cancer |
100% |
Not available |
Not available |
100% |
|
Radiation therapy administered within 1 year of diagnosis for women under age 70 receiving breast conserving surgery
|
91.8% (7 of the 8 women refused treatment)
|
82.1%
|
85.7%
|
100% |
|
Combination chemotherapy considered or administered within 4 months of diagnosis for women under age 70 with AJCCTlc, Stage II or III hormone receptor negative breast cancer
|
100%
|
84.1%
|
88.2%
|
100% |
|
Tamoxifen or third generation aromatase inhibitor considered or administered within 1 year of diagnosis for women with AJCCTlc, Stage ll or lll hormone receptor positive breast cancer
|
98.3%
|
73.6%
|
79.1%
|
100% |
The most recent ACoS CoC quality indicators, showing how Legacy ranks against our peers using the proportion of breast cancer patients treated according to nationally recognized standards of care. (Data is the most recent available, 2010.) NAPBC data is from 2012.